Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 39.9% during the third quarter, HoldingsChannel reports. The firm owned 36,382 shares of the biotechnology company’s stock after selling 24,152 shares during the quarter. Intech Investment Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,255,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Virtus Advisers LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth $34,000. Salomon & Ludwin LLC acquired a new stake in Arrowhead Pharmaceuticals in the third quarter valued at $34,000. Federated Hermes Inc. acquired a new stake in Arrowhead Pharmaceuticals in the third quarter valued at $52,000. Smartleaf Asset Management LLC lifted its holdings in Arrowhead Pharmaceuticals by 2,186.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,618 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 883.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock worth $66,000 after buying an additional 3,763 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Down 5.9%

ARWR opened at $59.82 on Friday. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The stock has a market capitalization of $8.38 billion, a P/E ratio of 39.10 and a beta of 1.23. The business’s 50-day simple moving average is $65.46 and its 200-day simple moving average is $49.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company’s quarterly revenue was up 10461.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.39) EPS. Analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the transaction, the director directly owned 33,600 shares of the company’s stock, valued at approximately $2,273,376. The trade was a 22.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 13,187 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $66.10, for a total transaction of $871,660.70. Following the transaction, the chief executive officer owned 3,792,739 shares in the company, valued at approximately $250,700,047.90. This trade represents a 0.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 485,836 shares of company stock valued at $32,117,910. 3.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARWR. Morgan Stanley increased their price objective on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a report on Wednesday, January 7th. Bank of America boosted their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. The Goldman Sachs Group increased their price target on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. Finally, Chardan Capital boosted their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.